Home › Cases › NSTEMI in a Diabetic Patient
NSTEMI
NSTEMI in a Diabetic Patient
6 questions
Question 1 · Silent ischaemia
Correct answer: Diabetic autonomic neuropathy impairs ischaemic pain perception — 'silent ischaemia' is 2-3x more common in diabetes
Why
Silent ischaemia in diabetes: autonomic neuropathy impairs visceral pain sensation including cardiac pain. Diabetic patients frequently present with atypical symptoms (fatigue, nausea, dyspnoea, vomiting) rather than chest pain. May present late or only on investigation. Always have higher index of suspicion for ACS in diabetic patients.
Key point
Diabetic autonomic neuropathy → silent ischaemia. Atypical symptoms (fatigue, nausea) without chest pain. High suspicion.
Question 2 · Glycaemic control in ACS
Correct answer: Target glucose 6-10 mmol/L. Avoid hypoglycaemia — associated with worse ACS outcomes. Insulin infusion if needed, with regular glucose monitoring
Why
Glycaemia in ACS: admission hyperglycaemia is a poor prognostic marker, even without diabetes. Target 6–10 mmol/L and avoid hypoglycaemia. Its catecholamine surge increases myocardial workload and can provoke ischaemia or arrhythmias. Use dose-adjusted insulin with regular glucose monitoring when needed. Routine glucose-insulin-potassium (GIK) is not recommended; CREATE-ECLA found no 30-day mortality benefit in STEMI.
Key point
ACS glycaemia target 6-10 mmol/L. AVOID HYPOGLYCAEMIA — causes catecholamine surge → worse outcomes.
Question 3 · Metformin post-contrast
Correct answer: Withhold metformin now; do not delay urgent angiography. Restart no earlier than 48h afterwards, only once renal function is reassessed and stable
Why
AKI can cause metformin accumulation and lactic acidosis. Withhold now; do not delay urgent angiography for a 48h washout. Recheck renal function and restart no earlier than 48h after contrast, once stable and otherwise suitable for metformin. Stable patients without AKI need assessment of renal function and contrast route; an eGFR<60 rule is not universal.
Key point
AKI + contrast: withhold metformin now. Do not delay urgent angiography. Restart ≥48h later only after renal reassessment confirms suitability.
Question 4 · Prognosis in diabetes
Correct answer: Diabetes significantly worsens NSTEMI outcomes: higher mortality, higher re-infarction, more complex coronary disease (diffuse, small vessel), more heart failure
Why
Diabetes + NSTEMI: higher mortality, with the size of the increase varying by population and follow-up. More likely to have 3-vessel disease, diffuse small-vessel disease (harder to revascularise) and heart failure. Patients with diabetes may benefit more from early angiography; use the same clinical-risk criteria as without diabetes. GRACE and guideline-directed medical therapy remain important.
Key point
DM + NSTEMI: higher mortality, more diffuse coronary disease and heart failure. Use GRACE and clinical instability to guide invasive care; diabetes may increase its benefit.
Question 5 · SGLT2 in post-MI heart failure
Correct answer: SGLT2 inhibitor (empagliflozin/dapagliflozin) — reduces HF hospitalisation and cardiovascular death in heart failure with reduced EF, regardless of diabetes status
Why
Dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) reduced the combined risk of worsening HF/HF hospitalisation or cardiovascular death in HFrEF, with or without diabetes. EMPA-REG studied people with type 2 diabetes and established cardiovascular disease. Use the HFrEF evidence for this patient once clinically stable.
Key point
SGLT2 inhibitor in HFrEF: reduces HF hospitalisation and CV death. Benefit regardless of diabetes. Now standard HFrEF.
Question 6 · Cardiac rehabilitation
Correct answer: Cardiac rehabilitation programme — supervised exercise, medication adherence and lifestyle counselling; reduces recurrent MI and hospital admissions
Why
Cardiac rehabilitation combines exercise, education and psychological support after MI, supporting fitness, quality of life and medication adherence. Cochrane found fewer recurrent MIs and admissions; the medium-term estimate was 23% lower cardiovascular mortality at >12–36 months, not a universal 20–25% reduction in all-cause mortality. Arrange referral before discharge; invite to a session within 10 days.
Key point
Cardiac rehab: exercise, education and support reduce recurrent events. Arrange before discharge; first session within 10 days.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.